287 related articles for article (PubMed ID: 21635858)
1. [Level of evidence for therapeutic drug monitoring of posaconazole].
Lefeuvre S; Jelassi ML; Benlmouden A; Berge M; Le Guellec C; Billaud EM;
Therapie; 2011; 66(2):115-22. PubMed ID: 21635858
[TBL] [Abstract][Full Text] [Related]
2. [Not Available].
Lefeuvre S; Jelassi ML; Benlmouden A; Berge M; Le Guellec C; Billaud EM;
Therapie; 2011; 66(2):115-22. PubMed ID: 27393646
[TBL] [Abstract][Full Text] [Related]
3. [Level of evidence for therapeutic drug monitoring of voriconazole].
Hulin A; Dailly E; Le Guellec C;
Therapie; 2011; 66(2):109-14. PubMed ID: 21635857
[TBL] [Abstract][Full Text] [Related]
4. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients.
Berge M; Guillemain R; Boussaud V; Pham MH; Chevalier P; Batisse A; Amrein C; Dannaoui E; Loriot MA; Lillo-Le Louet A; Billaud EM
Transpl Infect Dis; 2009 Jun; 11(3):211-9. PubMed ID: 19302272
[TBL] [Abstract][Full Text] [Related]
5. Posaconazole: an extended-spectrum triazole antifungal agent.
Schiller DS; Fung HB
Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
[TBL] [Abstract][Full Text] [Related]
6. Posaconazole: an oral triazole with an extended spectrum of activity.
Rachwalski EJ; Wieczorkiewicz JT; Scheetz MH
Ann Pharmacother; 2008 Oct; 42(10):1429-38. PubMed ID: 18713852
[TBL] [Abstract][Full Text] [Related]
7. Lack of evidence for exposure-response relationship in the use of posaconazole as prophylaxis against invasive fungal infections.
Cornely OA; Ullmann AJ
Clin Pharmacol Ther; 2011 Mar; 89(3):351-2. PubMed ID: 21270787
[No Abstract] [Full Text] [Related]
8. [The latest data on posaconazole].
Paugam A
Med Mal Infect; 2007 Feb; 37(2):71-6. PubMed ID: 17267154
[TBL] [Abstract][Full Text] [Related]
9. Posaconazole therapeutic drug monitoring in the real-life setting: a single-center experience and review of the literature.
Gross BN; Ihorst G; Jung M; Wäsch R; Engelhardt M
Pharmacotherapy; 2013 Oct; 33(10):1117-25. PubMed ID: 23864486
[TBL] [Abstract][Full Text] [Related]
10. Subtherapeutic Posaconazole Exposure and Treatment Outcome in Patients With Invasive Fungal Disease.
van der Elst KC; Brouwers CH; van den Heuvel ER; van Wanrooy MJ; Uges DR; van der Werf TS; Kosterink JG; Span LF; Alffenaar JW
Ther Drug Monit; 2015 Dec; 37(6):766-71. PubMed ID: 26565789
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease.
Krishna G; Martinho M; Chandrasekar P; Ullmann AJ; Patino H
Pharmacotherapy; 2007 Dec; 27(12):1627-36. PubMed ID: 18041883
[TBL] [Abstract][Full Text] [Related]
12. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study.
Soler-Palacín P; Frick MA; Martín-Nalda A; Lanaspa M; Pou L; Roselló E; de Heredia CD; Figueras C
J Antimicrob Chemother; 2012 Mar; 67(3):700-6. PubMed ID: 22190607
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients.
Winston DJ; Bartoni K; Territo MC; Schiller GJ
Biol Blood Marrow Transplant; 2011 Apr; 17(4):507-15. PubMed ID: 20460163
[TBL] [Abstract][Full Text] [Related]
14. Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update.
Smith WJ; Drew RH; Perfect JR
Expert Rev Anti Infect Ther; 2009 Mar; 7(2):165-81. PubMed ID: 19254165
[TBL] [Abstract][Full Text] [Related]
15. Numbers needed to treat with posaconazole prophylaxis to prevent invasive fungal infection and death.
Cornely OA; Ullmann AJ
Clin Infect Dis; 2008 May; 46(10):1626-7; author reply 1627-8. PubMed ID: 18419501
[No Abstract] [Full Text] [Related]
16. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma.
Jang SH; Colangelo PM; Gobburu JV
Clin Pharmacol Ther; 2010 Jul; 88(1):115-9. PubMed ID: 20505665
[TBL] [Abstract][Full Text] [Related]
17. Safety of triazole antifungal drugs in patients with cancer.
Cronin S; Chandrasekar PH
J Antimicrob Chemother; 2010 Mar; 65(3):410-6. PubMed ID: 20035021
[TBL] [Abstract][Full Text] [Related]
18. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections.
Pascual A; Csajka C; Buclin T; Bolay S; Bille J; Calandra T; Marchetti O
Clin Infect Dis; 2012 Aug; 55(3):381-90. PubMed ID: 22610925
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of posaconazole in the prophylaxis of invasive fungal infections in acute leukaemia patients for the French healthcare system.
Michallet M; Gangneux JP; Lafuma A; Herbrecht R; Ribaud P; Caillot D; Dupont B; Moreau P; Berger P; O'Sullivan AK
J Med Econ; 2011; 14(1):28-35. PubMed ID: 21175376
[TBL] [Abstract][Full Text] [Related]
20. [Triazole antifungal agents: practice guidelines of therapeutic drug monitoring and perspectives in treatment optimization].
Scodavolpe S; Quaranta S; Lacarelle B; Solas C
Ann Biol Clin (Paris); 2014; 72(4):391-404. PubMed ID: 25119797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
